Table 1 Demographic, genetic, and biochemical data in the total cohort as well as divided into three age tertiles
From: Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations
Total cohort (n = 716) | ≤45 years (n = 237) | 46–64 years (n = 242) | ≥65 years (n = 237) | |
|---|---|---|---|---|
Demographic | ||||
Age (years), mean (range) | 53.3 (17–99) | 29.9 (17–45) | 57.3 (46–64) | 72.6 (65–99) |
Male, n (%) | 305 (42.6) | 114 (48.1) | 104 (43.0) | 87 (36.7) |
Female, n (%) | 411 (57.4) | 123 (51.9) | 138 (57.0) | 150 (63.3) |
Genetic | ||||
APOE ε4–/–, n (%) | 506 (70.7) | 162 (68.4) | 172 (71.1) | 172 (72.6) |
APOE ε4+/–, n (%) | 190 (26.5) | 69 (29.1) | 64 (26.4) | 57 (24.1) |
APOE ε4+/+, n (%) | 20 (2.8) | 6 (2.5) | 6 (2.5) | 8 (3.4) |
Biochemical: CSF Aβ42 (ng/L), mean (SD) | ||||
All genotypes | 252.1 (71.0) | 251.9 (67.8) | 264.9 (67.7) | 239.2 (75.2) |
APOE ε4–/– | 261.2 (70.9) | 257.2 (69.5) | 274.5 (68.1) | 251.8 (73.4) |
APOE ε4+/– | 234.8 (65.4) | 241.4 (64.0) | 248.1 (58.3) | 211.9 (69.7) |
APOE ε4+/+ | 185.5 (59.0) | 231.3 (51.8) | 167.8 (39.1) | 164.4 (62.1) |
P value* | <0.001 | 0.203 | <0.001 | <0.001 |